Homestead Associates In Research | Homestead, FL

Research site

(Unclaimed)

Location

27535 S Dixie Highway, Homestead, Florida, United States of America

Site insights

Top conditions

Top treatments

MK-6024

SEL-212

Semaglutide

Teriflunomide

RO7790121

Apalutamide

Remibrutinib

MTX

JNJ-53718678

Inebilizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 20 total trials

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatit...

Enrolling

Metabolic Dysfunction-associated Steatotic Liver Disease

Non-alcoholic Fatty Liver Disease

Combination Product: Efinopegdutide

Combination Product: Placebo

A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

The main objective is to assess the safety and tolerability of inebilizumab (Subprotocol A) and subcutaneous (SC) blinatumomab (Subprotocol B) in adu...

Begins enrollment this month

Systemic Lupus Erythematosus

Drug: Blinatumomab

Drug: Inebilizumab

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relat...

Enrolling

Hepatic Impairment

Drug: Apalutamide

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

A Study to Assess the Efficacy and Safety of RO7790121 for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-1)

This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of RO7790121 compared with p...

Enrolling

Moderately to Severely Active Ulcerative Colitis

Drug: Placebo

Drug: RO7790121

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus peglot...

Enrolling

Gout

Drug: Methotrexate

Biological: Pegloticase

Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)

This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction fro...

Active, not recruiting

Nonalcoholic Fatty Liver Disease

Metabolic Dysfunction-Associated Steatotic Liver Disease

Drug: Efinopegdutide

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Enrolling

Relapsing Multiple Sclerosis

Drug: Teriflunomide

Drug: Remibrutinib

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to se...

Active, not recruiting

Ulcerative Colitis

Drug: Placebo

Drug: Efavaleukin alfa